Oleoylethanolamide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Oleoylethanolamide is a high affinity endogenous agonist of PPAR-α.In vitro studies showed that OEA inhibited transforming growth factor β1-stimulated HSCs activation through suppressing Smad2/3 phosphorylation, α-SMA expression and myofibroblast transformation.

Oleoylethanolamide is a high affinity endogenous agonist of PPAR-α.In vitro studies showed that OEA inhibited transforming growth factor β1-stimulated HSCs activation through suppressing Smad2/3 phosphorylation, α-SMA expression and myofibroblast transformation.Treatment with OEA (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuated the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs).?Gene expression analysis of hepatic tissues indicated that OEA inhibited the expression of α-smooth muscle action (α-SMA) and collagen matrix, fibrosis markers, and genes involved in inflammation and extracellular matrix remodeling.?

N-Oleoylethanolamide,Oleamide MEA,Oleic acid monoethanolamide

Proteasome/Ubiquitin

Endogenous Metabolite

Human Endogenous Metabolite;PPARα

——

——

111-58-0

325.53

C20H39NO2

>98% (HPLC)

DMSO:19.83 mg/mL (60.92 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)

CCCCCCCC\C=C/CCCCCCCC(=O)NCCO

——

(-20℃)

With Ice Pack

≥ 2 years